Medtronic Reports Strong Q3 FY2026 Results with 8.7% Revenue Growth

Details

GAAP diluted EPS was $0.89, while non-GAAP diluted EPS was $1.36, three cents ahead of Q3 guidance mid-point. The company reiterated its FY26 organic revenue growth and EPS guidance. Key highlights include an 11% year-over-year increase in the Cardiovascular portfolio and 80% growth in Cardiac Ablation Solutions. Medtronic also secured regulatory approvals for new products during the quarter.

Items reported

About Medtronic plc

Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.